Novavax Raises 2026 Revenue Outlook, Q2 Beat Fueled by Licensing Milestones
NVAX sits 26% above its 52-week low of $6.2.
Summary
Novavax raised its 2026 adjusted revenue forecast to $235M-$275M, up from $230M-$270M, after Q2 revenue of $57M beat the $52.51M consensus. The beat was driven by licensing milestone payments as the company pivots away from direct vaccine sales. A $125M milestone payment is contingent on Sanofi starting a late-stage COVID-flu combo trial, now in advanced regulatory discussions. An additional $75M is tied to a manufacturing tech transfer expected mid-2027. The net loss widened to $53M from a $107M profit a year ago, reflecting the transition. This follows the May 13D/A filing where activist Shah Capital demanded leadership changes and buybacks. The raised guidance and milestone clarity strengthen the licensing-focused turnaround narrative.
At the time of this announcement, NVAX was trading at $7.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.20 to $11.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.